PEGS_Banner_Engineering-Antibodies


The field of protein engineering is at an exciting point in its development, with new generations of therapeutic antibodies now reaching the market, great advances in protein science and a body of clinical evidence that can be used to inform the development of safe, highly effective therapies for unmet medical needs. At PEGS, Engineering Antibodies presents the state of the art in technologies used by protein engineers working at the discovery and design stage to quickly and efficiently craft biotherapeutics directed at the most elusive targets and biological functions. Emphasis will be given to new presentations that highlight unpublished work in this important field.

KEYNOTE PRESENTATION: NGS and Computational Motif Analysis to Identify the Antibody Epitope Specificities that Co-Associate with a Disease Phenotype

Patrick Daugherty, Ph.D., Professor, Chemical Engineering, Biomolecular Science and Engineering, University of California, Santa Barbara


ANTIBODY DISCOVERY FOR EMERGING TARGETS AND INDICATIONS 

A Monoclonal Antibody that Targets a NaV1.7 Channel Voltage Sensor for Pain and Itch Relief

Ru-Rong Ji, Ph.D., Professor, Department of Anesthesiology and Neurobiology, Duke University Medical Center

Rapid Development of Antibody Therapeutics for Infectious Disease Outbreaks

Wayne A. Marasco, M.D., Ph.D., Professor, Medicine, Harvard Medical School

Antibody Therapeutics for CNS Diseases and Delivery across the Blood Brain Barrier

George Thom, Senior Scientist, Antibody Discovery and Protein Engineering, MedImmune

Phage Display Derived Calcium-Dependent Biparatopic Antibody for Eliminating High Plasma Concentration Target Antigen

Shinya Ishii, Research Scientist, Research Division, Chugai Pharmaceutical Co., Ltd., Japan


NEW RESEARCH TECHNOLOGIES FOR PROTEIN ENGINEERING 

Single-Cell Sequencing and Analysis in Antibody Discovery

J. Christopher Love, Ph.D., Associate Professor, Chemical Engineering, Koch Institute, Massachusetts Institute of Technology

Multiplexing Technology to Measure the Specificity of Antibody Binding

Jonas V. Schaefer, Ph.D., Head, High-Throughput Laboratory, Department of Biochemistry, University of Zurich, Switzerland

A Pipeline for the Discovery of immunoPCR Reagents

Andrew Ellington, Ph.D., Research Professor of Biochemistry, University of Texas, Austin

Enhanced IgG Hexamerization Mediates Efficient C1q Docking and More Rapid and Substantial Complement-Dependent Cytotoxicity (CDC): Preclinical Proof-of-Concept

Janine Schuurman, Ph.D., Vice President, Research, Genmab, Denmark

Creating Focused Mutant Libraries for Protein Engineering

Alain Ajamian, Ph.D., Director, Chemical Computing Group

Michael Drummond, Ph.D., Applications Scientist, Chemical Computing Group


COMPUTATIONAL TOOLS IN ANTIBODY RESEARCH 

Computational Design of Protein Antigens

William R. Schief, Ph.D., Professor, Immunology and Microbial Science, The Scripps Research Institute

OptMAVEn: De novo Design of Antibody Variable Regions

Costas D. Maranas, Ph.D., Professor, Chemical Engineering, Pennsylvania State University

SPECIAL PRESENTATION: Current Intellectual Property Developments in Antibody Engineering

Konstantin M. Linnik, Ph.D., Partner, Intellectual Property, Nutter, McClennen & Fish, LLP


CHARACTERIZATION AND EXPLOITATION OF NATURAL IMMUNE RESPONSES 

NGS-Based Characterization of Antibody Responses Following Vaccination

Sai Reddy, Ph.D., Assistant Professor, Biosystems Science and Engineering, ETH Zurich, Switzerland

Ligand Discovery for T Cell Receptors Using Yeast Display

Michael Birnbaum, Researcher, Stanford University School of Medicine

Case Studies of Approaches for Efficiently Mining the Natural Antibody Repertoire

Daniel Lightwood, Ph.D., Director, Antibody Discovery, UCB-Celltech, United Kingdom

Realizing the Therapeutic Potential of Antibodies Derived from a Human Immune Response – Case Studies in Indications of Oncology and Infectious Disease

Kristine Swiderek, Ph.D., CSO, Theraclone Sciences


For more details on the conference, please contact:
Kent Simmons
Program Director
Cambridge Healthtech Institute
Phone: 207-869-9199
E-mail: ksimmons@healthtech.com 

For partnering and sponsorship information, please contact:
Jason Gerardi (Companies A-K)
Manager, Business Development
Cambridge Healthtech Institute
T: 781-972-5452
E: jgerardi@healthtech.com 

Carol Dinerstein (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: 781.972.5471
E: dinerstein@healthtech.com